8-K: Relmada Therapeutics' Phase 3 Trial for Depression Drug Deemed Futile in Interim Analysis

Relmada Therapeutics announced that its Phase 3 Reliance II trial for REL-1017 as an adjunctive treatment for major depressive disorder is unlikely to meet its primary efficacy endpoint based on an interim analysis.

Summary

• Relmada Therapeutics' Phase 3 Reliance II trial for REL-1017, a treatment for major depressive disorder, has been deemed futile after an interim analysis by the Data Monitoring Committee.
• The study is unlikely to meet its primary efficacy endpoint with statistical significance.
• No new safety concerns were identified during the interim analysis.
• Relmada will evaluate the full dataset to determine the next steps for the REL-1017 program.
• The company will continue to focus on the development of REL-P11 for metabolic disease, which is currently in a Phase 1 study.
• Relmada had approximately $54.1 million in cash and cash equivalents as of September 30, 2024.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the failure of the Phase 3 trial, which is a significant setback for the company's lead drug candidate. However, the company's focus on REL-P11 and its cash position provide some positive aspects.

Positives

• No new safety concerns were identified in the interim analysis of the Reliance II trial.
• Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024.
• The company is continuing to advance the Phase 1 study of REL-P11 for metabolic disease.

Negatives

• The Phase 3 Reliance II trial for REL-1017 is unlikely to meet its primary efficacy endpoint.
• The Data Monitoring Committee (DMC) deemed the trial futile based on an interim analysis.

Risks

• The failure of the Reliance II trial could impact the future of the REL-1017 program.
• There is a risk that the full dataset evaluation may not yield positive results for REL-1017.
• The development of REL-P11 for metabolic disease is still in early stages and may not be successful.
• The company's future success is dependent on the successful development and commercialization of its drug candidates.

Future Outlook

Relmada will evaluate the full dataset of the Reliance II trial to determine the next steps for the REL-1017 program and will continue to advance the Phase 1 study of REL-P11 for metabolic disease.

Management Comments

• We are disappointed with the outcome of this interim analysis, said Sergio Traversa, Chief Executive Officer of Relmada.
• Based on these results, Relmada will evaluate the full dataset to determine next steps for the REL-1017 program.
• We are grateful to the investigative sites and patients who participated in the REL-1017 program.

Industry Context

The failure of the Phase 3 trial highlights the challenges in developing effective treatments for major depressive disorder, a complex and difficult-to-treat condition. The company's pivot to focus on REL-P11 for metabolic disease reflects a strategic shift in response to the clinical trial results.

Comparison to Industry Standards

• The failure of a Phase 3 trial is not uncommon in the pharmaceutical industry, with many drug candidates failing to meet efficacy endpoints.
• Other companies developing treatments for MDD, such as Sage Therapeutics and Axsome Therapeutics, have also faced challenges in clinical trials.
• The focus on metabolic diseases with REL-P11 aligns with a growing interest in the potential of psilocybin and related compounds for treating various conditions, as seen with companies like Compass Pathways and MindMed.

Stakeholder Impact

• Shareholders may experience a negative impact due to the failure of the Phase 3 trial.
• Employees may face uncertainty regarding the future of the REL-1017 program.
• Patients with major depressive disorder may be disappointed by the setback in the development of REL-1017.

Next Steps

• Relmada will evaluate the full dataset of the Reliance II trial.
• Relmada will determine the next steps for the REL-1017 program.
• Relmada will continue to advance the Phase 1 study of REL-P11 for metabolic disease.

Key Dates

Keywords

REL-1017, REL-P11, Major Depressive Disorder, MDD, Metabolic Disease, Clinical Trial, Phase 3, Data Monitoring Committee, DMC, Interim Analysis, Efficacy, Biotechnology, Central Nervous System, CNS